Imara Inc. IMRA
We take great care to ensure that the data presented and summarized in this overview for IMARA Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IMRA
Top Purchases
Top Sells
About IMRA
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2?related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at IMRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 28
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,250
-6.21%
|
$58,500
$18.9 P/Share
|
|
Apr 28
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+11.02%
|
$6,500
$2.48 P/Share
|
|
Apr 21
2025
|
Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
5,000
-0.25%
|
$80,000
$16.38 P/Share
|
|
Apr 17
2025
|
Samuel Kintz PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
5,000
-0.5%
|
$80,000
$16.42 P/Share
|
|
Apr 07
2025
|
Anish Patel CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Indirect |
6,667
-0.69%
|
$120,006
$18.46 P/Share
|
|
Mar 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,250
-12.38%
|
$68,250
$21.33 P/Share
|
|
Mar 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+11.02%
|
$6,500
$2.48 P/Share
|
|
Mar 24
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-4.17%
|
$22,000
$22.5 P/Share
|
|
Mar 24
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.0%
|
$2,000
$2.48 P/Share
|
|
Mar 19
2025
|
Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
12,500
-1.23%
|
$250,000
$20.61 P/Share
|
|
Mar 17
2025
|
Samuel Kintz PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
12,500
-1.25%
|
$250,000
$20.83 P/Share
|
|
Mar 07
2025
|
Anish Patel CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Indirect |
6,667
-2.02%
|
$140,007
$21.44 P/Share
|
|
Mar 04
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.3%
|
$20,000
$2.48 P/Share
|
|
Feb 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,250
-20.0%
|
$65,000
$20.41 P/Share
|
|
Feb 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+16.67%
|
$6,500
$2.48 P/Share
|
|
Feb 07
2025
|
Anish Patel CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Indirect |
6,667
-1.98%
|
$140,007
$21.93 P/Share
|
|
Feb 05
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-7.14%
|
$22,000
$22.52 P/Share
|
|
Feb 05
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.67%
|
$2,000
$2.48 P/Share
|
|
Jan 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,250
-20.0%
|
$68,250
$21.59 P/Share
|
|
Jan 27
2025
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+16.67%
|
$6,500
$2.48 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 160K shares |
|---|
| Open market or private sale | 2.52M shares |
|---|